t
Haleon plc announced on 03 August 2026 that as at 31 July 2026, its total issued ordinary shares of £0.01 each amounted to 8,820,906,422, of which 11,879,800 were held as treasury shares. This results in 8,809,026,622 ordinary shares with voting rights, a figure shareholders are directed to use for notification calculations.
| Date | 3 Aug 2026 |
| Time | 09:00:00 |
| Category | Capital structure |
| ID | 8580O |
Haleon plc: Total Voting Rights and Capital
03 August 2026: As at 31 July 2026 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,820,906,422 ordinary shares of £0.01 each, of which 11,879,800 are held as treasury shares.
Therefore, the number of ordinary shares with voting rights is 8,809,026,622 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notifiable interests in Haleon may be sent to: [email protected]
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.